BACKGROUND: Long-term follow-up of heart, liver, and lung transplantation has led to an increased recognition of secondary end-stage renal failure (ESRF) in transplant recipients. This study examines our center's experience with renal transplantation following previous solid organ transplantation. METHODS: From January 1, 1992, to September 30, 1999, our center performed 18 renal transplants in previous solid organ recipients. During the same period, 815 total renal transplants were performed. One- and 3-year graft and patient survival, recipient demographics, donor type, and reason for transplantation were compared between these groups. RESULTS: Of the 18 recipients, 7 had prior heart transplants, 4 had prior liver transplants, and 7 had prior lung transplants. Cyclosporine toxicity contributed to renal failure in 17 (94.4%) of the patients-either as a sole factor (11 patients) or in combination with hypertension, renal artery stenosis, or tacrolimus toxicity (6 patients). Kaplan-Meier 1- and 3-year patient survival was 82.9% and 73.7%, compared with 95.5% and 90.7% in all renal transplant recipients. No surviving patient has suffered renal allograft loss. Mean current creatinine level is 1.4 mg/dL. CONCLUSIONS: Renal transplantation is an excellent therapy for ESRF following prior solid organ transplantation. One and 3-year patient and graft survival demonstrate the utility of renal transplantation in this patient population.
BACKGROUND: Long-term follow-up of heart, liver, and lung transplantation has led to an increased recognition of secondary end-stage renal failure (ESRF) in transplant recipients. This study examines our center's experience with renal transplantation following previous solid organ transplantation. METHODS: From January 1, 1992, to September 30, 1999, our center performed 18 renal transplants in previous solid organ recipients. During the same period, 815 total renal transplants were performed. One- and 3-year graft and patient survival, recipient demographics, donor type, and reason for transplantation were compared between these groups. RESULTS: Of the 18 recipients, 7 had prior heart transplants, 4 had prior liver transplants, and 7 had prior lung transplants. Cyclosporinetoxicity contributed to renal failure in 17 (94.4%) of the patients-either as a sole factor (11 patients) or in combination with hypertension, renal artery stenosis, or tacrolimus toxicity (6 patients). Kaplan-Meier 1- and 3-year patient survival was 82.9% and 73.7%, compared with 95.5% and 90.7% in all renal transplant recipients. No surviving patient has suffered renal allograft loss. Mean current creatinine level is 1.4 mg/dL. CONCLUSIONS: Renal transplantation is an excellent therapy for ESRF following prior solid organ transplantation. One and 3-year patient and graft survival demonstrate the utility of renal transplantation in this patient population.
Authors: James R Cassuto; Matthew H Levine; Peter P Reese; Roy D Bloom; Simin Goral; Ali Naji; Peter L Abt Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: J R Cassuto; P P Reese; S Sonnad; R D Bloom; M H Levine; K M Olthoff; A Shaked; A Naji; P Abt Journal: Am J Transplant Date: 2010-11 Impact factor: 8.086
Authors: Christine E Haugen; Xun Luo; Courtenay M Holscher; Mary G Bowring; Sandra R DiBrito; Jacqueline Garonzik-Wang; Mara McAdams-DeMarco; Dorry L Segev Journal: Transplantation Date: 2019-11 Impact factor: 4.939
Authors: Titte R Srinivas; Brian R Stephany; Marie Budev; David P Mason; Randall C Starling; Charles Miller; David A Goldfarb; Stuart M Flechner; Emilio D Poggio; Jesse D Schold Journal: Clin J Am Soc Nephrol Date: 2010-09-02 Impact factor: 8.237
Authors: Stefan Roest; Dennis A Hesselink; Dominika Klimczak-Tomaniak; Isabella Kardys; Kadir Caliskan; Jasper J Brugts; Alexander P W M Maat; Michał Ciszek; Alina A Constantinescu; Olivier C Manintveld Journal: ESC Heart Fail Date: 2020-02-05